Scrip is part of Pharma Intelligence UK Limited

This site is operated by Pharma Intelligence UK Limited, a company registered in England and Wales with company number 13787459 whose registered office is 5 Howick Place, London SW1P 1WG. The Pharma Intelligence group is owned by Caerus Topco S.à r.l. and all copyright resides with the group.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


UK Offers Pharma Firms Ferry Tickets To Avoid No-Deal Brexit Supply Disruptions

Executive Summary

The UK health department says it has purchased ferry tickets that pharmaceutical companies can buy in order to transport their medicines and other product using alternative shipping routes between EU and UK ports in the event of a no-deal Brexit. It has also updated companies on how they can access additional warehousing space for medicine stockpiles.

You may also be interested in...

‘Keep Planning For No-Deal Brexit,’ UK Govt Tells Pharma As Chaos Grows

Amid the growing mayhem in parliament over the Brexit process, life science companies have been advised to continue preparing for the possibility that the UK might leave the EU without a deal at the end of next week. 

EU Offers Flexibility On UK Batch Release In No-Deal Brexit Scenario

The UK has been offered an exemption from the requirement for UK medicines to undergo EU batch testing and release before they can be marketed in member states of the EU, but only in specific circumstances.

How The UK Regulatory System Would Work In A No-Deal Brexit – Part 2

In this second article on the regulations published by the government on how the UK would regulate medicines in a “no-deal” Brexit scenario, we look at what is being proposed for areas such as pediatric investigation plans, orphan medicines, pharmacovigilance, parallel trade, generics approvals, and good manufacturing and distribution practices.


Latest Headlines
See All



Ask The Analyst

Ask the Analyst is free for subscribers.  Submit your question and one of our analysts will be in touch.

Thank you for submitting your question. We will respond to you within 2 business days. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts